Medicare Officially Limits Coverage of Aduhelm to Patients in Clinical Trials

Written by

in

Officials cited data showing the new Alzheimer’s drug has serious safety risks and may not help patients.

Author: PAM BELLUCK

Aduhelm (Drug) Alzheimer’s Assn Alzheimer’s Disease Biogen Inc Centers for Medicare and Medicaid Services Clinical Trials Drugs (Pharmaceuticals) Food and Drug Administration Health Insurance and Managed Care Medicare

Comments

Leave a ReplyCancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

More posts